A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Thiomersal (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Sponsors Beech Tree Labs
- 09 Apr 2021 Status changed from recruiting to completed.
- 09 Feb 2021 Planned End Date changed from 1 Feb 2021 to 1 Jul 2021.
- 09 Feb 2021 Planned primary completion date changed from 31 Jan 2021 to 30 Jun 2021.